down arrow

Realcan Pharmaceutical Group Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000013X5
  • SHE: 002589
CNY
3.59
-0.01 (-0.28%)

Sep 22

SHE

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Realcan Pharmaceutical Group Co., Ltd.

Why is Realcan Pharmaceutical Group Co., Ltd. ?

1
Poor Management Efficiency with a low ROCE of 2.78%
  • The company has been able to generate a Return on Capital Employed (avg) of 2.78% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
  • Poor long term growth as Net Sales has grown by an annual rate of -23.26% and Operating profit at -54.08% over the last 5 years
  • The company is Net-Debt Free
  • The company has been able to generate a Return on Equity (avg) of 2.68% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of -23.26% and Operating profit at -54.08% over the last 5 years
4
Positive results in Mar 26
  • PRE-TAX PROFIT(Q) At CNY 16.32 MM has Grown at 958.94%
  • NET PROFIT(Q) At CNY 10.37 MM has Grown at 365.37%
  • INVENTORY TURNOVER RATIO(HY) Highest at 9.64 times
5
With ROE of 0.65%, it has a fair valuation with a 0.60 Price to Book Value
  • Over the past year, while the stock has generated a return of -11.11%, its profits have risen by 814.4% ; the PEG ratio of the company is 0.1
  • At the current price, the company has a high dividend yield of 0.2
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Realcan Pharmaceutical Group Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Realcan Pharmaceutical Group Co., Ltd. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Realcan Pharmaceutical Group Co., Ltd.
23.79%
0.28
44.44%
China Shanghai Composite
3.23%
1.20
14.07%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
-23.26%
EBIT Growth (5y)
-54.08%
EBIT to Interest (avg)
-0.17
Debt to EBITDA (avg)
36.23
Net Debt to Equity (avg)
0.45
Sales to Capital Employed (avg)
0.60
Tax Ratio
100.00%
Dividend Payout Ratio
18.35%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.11%
ROE (avg)
2.68%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
108
Industry P/E
Price to Book Value
0.69
EV to EBIT
243.81
EV to EBITDA
37.24
EV to Capital Employed
0.80
EV to Sales
0.89
PEG Ratio
0.13
Dividend Yield
0.16%
ROCE (Latest)
0.33%
ROE (Latest)
0.65%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company
NET PROFIT(HY)

Higher at CNY 11.14 MM

RAW MATERIAL COST(Y)

Fallen by -57.52% (YoY

PRE-TAX PROFIT(Q)

Highest at CNY 21.74 MM

-6What is not working for the Company
NET PROFIT(Q)

At CNY 0.76 MM has Fallen at -52.89%

NET SALES(Q)

Lowest at CNY 1,707.26 MM

Here's what is working for Realcan Pharmaceutical Group Co., Ltd.

Pre-Tax Profit
At CNY 21.74 MM has Grown at 778.19%
over average net sales of the previous four periods of CNY -3.21 MM
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Pre-Tax Profit
Highest at CNY 21.74 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Raw Material Cost
Fallen by -57.52% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Realcan Pharmaceutical Group Co., Ltd.

Net Profit
At CNY 0.76 MM has Fallen at -52.89%
over average net sales of the previous four periods of CNY 1.62 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (CNY MM)

Net Sales
Lowest at CNY 1,707.26 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (CNY MM)

Non Operating Income
Highest at CNY 0.58 MM
in the last five periods
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating income

Footer loading